1,010 results on '"Kukreti, Vishal"'
Search Results
252. Light Chain Deposition Disease: Impact of Stem Cell Tranplant on Hematological Response Achievement.
253. A Retrospective Study on the Incidence of Rituximab-Related Interstitial Pneumonitis In Patients Undergoing Immunochemotherapy for Non-Hodgkin Lymphoma
254. Phase I-II Trial of Oral Cyclophosphamide, Prednisone and Lenalidomide (Revlimid®) (CPR) for the Treatment of Patients with Relapsed and Refractory Multiple Myeloma
255. Cyclophosphamide and Prednisone Induction Effectively Decreased the Incidence of Engraftment Syndrome In Patients with POEMS Syndrome Who Undergo Stem Cell Transplantation.
256. Lenalidomide (Revlimid), Bortezomib (Velcade) and Dexamethasone (RVD) for Heavily Pretreated Relapsed or Refractory Multiple Myeloma
257. Incidence and Characteristics of Secondary Myelodysplastic Syndrome Developing During Lenalidomide-Based Regimens In Relapsed and/or Refractory Multiple Myeloma Patients
258. High-Dose Melphalan for AL Amyloidosis: The Importance of Case Selection to Improve Clinical Outcomes
259. Prospective Canadian Trial In Newly Diagnosed Multiple Myeloma Patients with t(4;14): Bortezomib-Based Therapy without ASCT
260. Neutropenia and G-CSF Use In Patients with Relapsed/Refractory Multiple Myeloma Treated with Lenalidomide Plus Dexamethasone
261. Autologous Stem Cell Transplantion for Adolescents and Young Adults with Relapsed and Refractory Hodgkin Lymphoma
262. Baseline Peripheral Neuropathy Does Not Impact the Efficacy and Tolerability of the Novel Proteasome Inhibitor Carfilzomib (CFZ): Results of a Subset Analysis of a Phase 2 Trial In Patients with Relapsed and Refractory Multiple Myeloma (R/R MM)
263. Two distinct syndromes of lymphoma associated AL amyloidosis: A case series and review of the literature
264. Once- versus twice-weekly bortezomib induction therapy with CyBorD in newly diagnosed multiple myeloma
265. Two Distinct Syndromes of Lymphoma-Associated Amyloidosis: Findings From a Case Series.
266. Prolonged Use of Lenalidomide (≥12 Cycles) for Multiple Myeloma (MM) Is Frequently Affected by Dose-Limiting Thrombocytopenia but Is Associated with Improved Quality of Response and Survival.
267. Low Risk of Reactivation of Hepatitis B and Hepatic Injury in Multiple Myeloma (MM) Patients (pts) Undergoing Autologous Stem Cell Transplant (ASCT).
268. Second Autologous Stem Cell Transplant (ASCT) as Salvage Therapy in Patients with Relapsed Multiple Myeloma.
269. A Phase II Trial Comparison of Once Versus Twice Weekly Bortezomib in CYBORD Chemotherapy for Newly Diagnosed Myeloma: Identical High Response Rates and Less Toxicity.
270. Alkaline Phosphatase (ALP) Variation During Carfilzomib Treatment Is Associated to Best Response in Multiple Myeloma.
271. Spontaneous Remission in a Patient With t(4;14) Translocation Multiple Myeloma
272. Stem Cell Mobilization Capacity Is Not a Predictor of Survival in Multiple Myeloma (MM) After Autologous Stem Cell Transplantation (ASCT).
273. Sequencing Novel Agents in Relapsed/Refractory Multiple Myeloma: Use of Bortezomib-Based Therapy After Lenalidomide + Dexamethasone.
274. Phase I-II Trial of Oral Cyclophosphamide, Prednisone and Lenalidomide (Revlimid®) (CPR) for the Treatment of Patients with Relapsed and Refractory Multiple Myeloma.
275. Bortezomib-Based Therapy, without Stem Cell Transplantation, for Newly Diagnosed Multiple Myeloma Patients with t(4;14).
276. Activity with Thalidomide-Based Therapy Following Lenalidomide Plus Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma.
277. Elderly Multiple Myeloma (MM) Patients (≥70 years) Can Safely Undergo Autologous Stem Cell Transplantation (ASCT) but Have Shorter Overall Survival Than Younger Patients (<70 years).
278. “Longterm Survival (≥10 years) in Multiple Myeloma (MM) Is Associated with Longer Duration of Therapy and Improved Quality of Response to Novel agents”.
279. Infectious Complications in Advanced Relapsed/Refractory Multiple Myeloma Patients Treated with Lenalidomide (Revlimid +/- Corticosteroids).
280. Age 40 Years and Under Does Not Confer Superior Prognosis in Patients with Multiple Myeloma Undergoing Upfront Autologous Stem Cell Transmplant
281. Evaluation of Serum Free Light Chains and Outcome in Multiple Myeloma Patients with an Intact Monoclonal Immunoglobulin Treated with Autologous Stem Cell Transplantation.
282. Steroid Refractoriness, but Not Rapidity of Response, to Induction Therapy Predicts for Outcome Post-Autologous Stem Cell Transplant (ASCT) in Patients (Pts) with Multiple Myeloma (MM)
283. A Phase II Study of Lenalidomide in Previously Untreated, Symptomatic Chronic Lymphocytic Leukemia (CLL)
284. Phase I-II Trial of Oral Cyclophosphamide, Prednisone and Lenalidomide (Revlimid®) (CPR) for the Treatment of Patients with Relapsed and Refractory Multiple Myeloma.
285. Treatment of Relapsed and Refractory Multiple Myeloma in Patients with p53 Deletion.
286. Phase I-II Trial of Bortezomib Plus Oral Cyclophosphamide and Prednisone in Relapsed and Refractory Multiple Myeloma
287. Small Intestinal B-Cell Lymphoma in a Patient With Lymphangiectasia Secondary to Abdominal Lymphangioma
288. Long-term survival in two patients with hepatosplenic T cell lymphoma treated with interferon-alpha
289. Autologous Stem Cell Transplantation (ASCT) in Multiple Myeloma (MM) Patients with Dialysis-Dependent Renal Failure Is Effective but Carries High Rates of Toxicity.
290. Spontaneous Tumoural Regression in a Patient with t(4;14) Translocation Multiple Myeloma. A Case Report.
291. A Phase II Study of Lenalidomide in Previously Untreated, Symptomatic Chronic Lymphocytic Leukemia (CLL).
292. A Phase II Trial of Myeloma Induction Therapy with Cyclophosphamide, Bortezomib, and Dexamethasone (Cybor-D): Improved Response over Historical Lenalidomide-Dexamethasone Controls.
293. Second Autologous Stem Cell Transplant (ASCT) as Salvage Therapy in Patients with Relapsed Multiple Myeloma: Improved Outcomes in Patients with Longer Disease Free Interval after First ASCT.
294. Autologous Stem Cell Transplantation (ASCT) in Multiple Myeloma (MM) Patients over Age 70.
295. Effect of the Percent Decrease in Monoclonal Protein with Induction Therapy on the Outcome after Autologous Stem Cell Transplantation in Patients with IgG and IgA Multiple Myeloma.
296. Age under 40 Does Not Confer Superior Prognosis in Patients with Multiple Myeloma Undergoing Upfront Autologous Stem Cell Transplant Despite High Response Rates.
297. p53 Deletion Yields High Response Rates but Rapid Progression and Poor Overall Survival in Multiple Myeloma Patients Undergoing Autologous Stem Cell Transplantation.
298. Alemtuzumab and CHOP Chemotherapy for the Treatment of Aggressive Histology Peripheral T Cell Lymphomas: A Multi-Center Phase I Study.
299. Primary Marginal Zone Lymphoma of the Subcutis Associated With Panniculitis and Fat Necrosis.
300. Tolerability of Velcade (Bortezomib) subcutaneous administration using a maximum volume of 3mL per injection site.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.